Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update basliginda one cikan gelisme: Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.